B-cell dyscrasias are disorders of the plasma cells, characterised by the abnormal proliferation of a monoclonal population of plasma cells that may or may not secrete detectable levels of a monoclonal immunoglobulin or immunoglobulin fragment (paraprotein or M protein).
This group includes multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), solitary plasmacytoma of bone, extramedullary plasmacytoma, Waldenström’s macroglobulinemia (WM), primary amyloidosis, light chain deposition disease, paraproteinemia, and heavy-chain disease.
Abingdon Health is addressing unmet clinical needs in this area with the introduction of rapid and near patient tests for diagnosis and monitoring of B-cell dyscrasias. The first product to market is Seralite® – FLC, a device for the quantitative analysis of free light chains.
Seralite® – FLC Serum
Rapid test for the quantitative measurement of free light chains (FLCs) in diagnosis and monitoring of multiple myeloma.Discover Seralite® - FLC
£2.5m National Lottery bid secured for the Forest of Dean https://t.co/tmjdioqnFJ
25 April 2017
© Abingdon Health 2017